On July 21, 2025, AstraZeneca revealed plans to invest $50 billion in U.S. manufacturing and R&D infrastructure by 2030. The initiative aims to help the company achieve its $80 billion revenue target by the end of the decade, with half of that expected to come from the U.S. market.
Among the facilities will be a multi-billion-dollar manufacturing facility in Virginia to specialize in treatments for chronic diseases. The facility, set to be the company’s largest single manufacturing investment, will produce AstraZeneca’s weight management and metabolic portfolio (e.g., oral GLP-1, baxdrostat, oral PCSK9), small molecules, peptides, and oligonucleotides.
During the next five years, the company also plans on expanding its R&D facility in Gaithersburg, Maryland; building a R&D center in Cambridge, Massachusetts; and expanding R&D for novel medicines. New manufacturing facilities will include cell therapy facilities in Rockville, Maryland and Tarzana, California. The company will expand continuous manufacturing capabilities at its Mount Vernon, Indiana facility and specialty manufacturing at its Coppell, Texas facility. New sites for the supply of clinical trial materials are also planned.
“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,” Pascal Soriot, chief executive officer, AstraZeneca, said in a press release (1). “It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology and will strengthen the country’s domestic supply chain for medicines.”
“For decades Americans have been reliant on foreign supply of key pharmaceutical products,” Howard Lutnick, US Secretary of Commerce, said in the press release (1). “President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”
Governor Glenn Youngkin, Commonwealth of Virginia, added (1), “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”
This new investment is in addition to the $3.5 billion US expansion the company announced in November 2024 (2) for an R&D center in Cambridge, Massachusetts; a biologics manufacturing facility in Maryland; and specialty manufacturing capabilities in Texas.
“Our multi-billion-dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States,” Soriot said in a press release at the time of the announcement (2). “By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”
1. AstraZeneca.
2. AstraZeneca. AstraZeneca Invests $3.5 Billion in R&D and Manufacturing in the United States. Press Release. Nov. 12, 2024.
